Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02002598 · OUTCOME

Number of Adverse Events (AEs)

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma · Source last updated 2024-09-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Adverse Events
Interval / dispersion
Not reported
Time frame
30 Days Post Last Dose, Up to approximately 9 months

What was measured

Total number of AEs observed.

Groups in this outcome

CFZ With Bendamustine and Dexamethasone

All participants who received at least two cycles of CFZ either at 27mg/m\^2, 36mg/m\^2, 45 mg/m\^2, or 56mg/m\^2.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
CFZ With Bendamustine and Dexamethasone20

Reported measurements

Source class 1
Values in Adverse Events · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
CFZ With Bendamustine and Dexamethasone106Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        106
denoms
  1. counts
    1. group Id
      OG000
      value
      20
    units
    Participants
description
Total number of AEs observed.
groups
  1. description
    All participants who received at least two cycles of CFZ either at 27mg/m\^2, 36mg/m\^2, 45 mg/m\^2, or 56mg/m\^2.
    id
    OG000
    title
    CFZ With Bendamustine and Dexamethasone
param Type
NUMBER
reporting Status
POSTED
time Frame
30 Days Post Last Dose, Up to approximately 9 months
title
Number of Adverse Events (AEs)
type
SECONDARY
unit Of Measure
Adverse Events

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice